サインイン

このコンテンツを視聴するには、JoVE 購読が必要です。 サインイン又は無料トライアルを申し込む。

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Representative Results
  • Discussion
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

Chemical genetics involves the substitution of a gatekeeper residue with an amino acid containing a different side chain at the target locus. Here, we have generated a mutant parasite containing a hypomorphic allele of cdpk1 and identified compensatory pathways adopted by the parasite in the mutant background.

Abstract

One of the mechanisms for subverting the effect of drugs by the malaria parasite is through rewiring of its transcriptome. The effect is more pronounced for target genes belonging to the multigene family. Plasmodium falciparum protein kinases belonging to the CDPK family are essential for blood stage development. As such, CDPKs are considered good targets for the development of anti-malarial compounds. The chemical genetics approach has been historically used to elucidate the function of protein kinases in higher eukaryotes. It requires the substitution of gatekeeper residue for another amino acid with a different side chain through genetic manipulation. Amino acid substitution at the gatekeeper position modulates the activity of a protein kinase and changes its susceptibility to a specific class of compounds known as bumped kinase inhibitors (BKIs) that help in the functional identification of the target gene. Here, we have exploited the chemical genetics approach to understand compensatory mechanisms evolved by a mutant parasite harboring a hypomorphic allele of cdpk1. Overall, our approach helps in identifying compensatory pathways that may be simultaneously targeted to prevent the development of drug resistance against individual kinases.

Introduction

Malaria is one of the leading infectious diseases that is responsible for millions of deaths every year, especially in children below 5 years of age1. There is no clinically available vaccine against malaria. Moreover, Plasmodium falciparum, the deadliest human malaria parasite, is known to have acquired resistance against the frontline drug called artemisinin2,3,4,5. There is an urgent necessity to identify new drug targets and novel strategies that can be quickly deployed to avoid the spread of artemisinin ....

Protocol

The P. falciparum parasite strain (NF54) was obtained from Alvaro Molina Cruz21,32,33. O+ human red blood cells used for the parasite culture were obtained from Rotary Blood Centre, New Delhi, India. The plasmids, pL6eGFP and pUF1, were obtained from Jose-Juan Lopez-Rubio. DSM267 was obtained from Margaret A. Phillips and Pradipsinh K. Rathod. WR99210 was provided by Jacobus Pharmaceutical Company.

Representative Results

Recombinant WT CDPK1 is expressed as a fusion protein with an N-terminal Glutathione S-transferase (GST) tag and purified using GST affinity chromatography. The purified CDPK1 protein was detected through Western blot using anti-CDPK1 and anti-GST antibodies (Figure 1). The threonine gatekeeper residue (T145) in WT CDPK1 was replaced with Met and Ser using site-directed mutagenesis to generate CDPK1T145M and CDPK1T145S mutant recombinant proteins, respectively (Figure 2<.......

Discussion

The generation of a mutant transgenic parasite containing a hypomorphic allele of cdpk1 is based on the in vitro kinase activity data with recombinant enzymes. It is better to generate as many mutant recombinant proteins with different gatekeeper residues as possible. Since the P. falciparum genome is highly AT-rich, therefore, expression of recombinant proteins in E. coli may require codon optimization. This will help in a comprehensive evaluation of gatekeeper substitution o.......

Acknowledgements

We acknowledge the support and facilities available through the Central Instrumentation Facility, School of Life Sciences, JNU. Financial support from the Department of Biotechnology (BT/PR28256/MED/29/1313/2018) to AB is also gratefully acknowledged. We thank Jose-Juan Lopez-Rubio for providing pL6eGFP and pUF1 plasmids. The funding agency has no role in the preparation and decision to publish the work. MS is a recipient of JRF-SRF Fellowship from the Council for Scientific and Industrial Research.

....

Materials

NameCompanyCatalog NumberComments
1x phosphate inhibitor cocktailSigma-Aldrich04906 845001
AflIINEBR0520S
Albumax II Gibco11021-037
Anti-GST antibodyThermoFisher ScientificG7781
Anti-Mouse HRPSigma-AldrichA4416
Anti-Rabbit HRPSigma-AldrichA6154
BamHINEBR3136S
BtgZ1NEBR0703S
CentrifugeThermoFisher ScientificSorvall legend micro 17R
Centrifuge ( For pelleting Bacterial cell)ThermoFisher ScientificSorvall ST 8R
Centrifuge ( For pelleting/processing parasite)ThermoFisher ScientificSorvall ST 8R (TX-400 rotor)
DpnINEBRO1765
D-Sorbitol Sigma-AldrichS1876
E. coli BLR(DE3) pLysS competent cellsSigma-Aldrich69956
E. coli DH5a Competent CellsTakara Bio9057
Electroporation Cuvettes, 0.2 cm gapBioRad1652086
ElectroporatorBioRadGenePulser Xcell
femtoLUCENTTM PLUS HRP chemiluminescent reagentG-Bioscience7860-003
GentamicinThermoFisher Scientific15750078
Giemsa StainHimediaS011-100ML
Glutathione Sepharose 4BGE Healthcare17075601
HEPES, Free AcidMerck391338
HypoxanthineMerck4010CBC
In-fusion HD cloning KitTakara Bio1711641A
iQ SYBR Green SupermixBioRad1708880EDU
MBP, dephosphorylated Merck13-110
NotINEBR3189S
Nucleobond Xtra Maxi EF  Takara Bio740424
NucleoSpin Gel and PCR clean-up Mini kitTakara Bio740609
PercollGE Healthcare17-0891-01
p-nitrobenzyl mesylate (PNBM)AbcamAb138910
Primestar Max DNA PolymeraseTakara BioR045A
Protease inhibitor cocktailRoche11836170001
Qiaprep Spin Miniprep Kit Qiagen27106
QuikChange II XL site-directed mutagenesis kitAgilent200521
RNeasy Mini kitQiagen74104
RPMI-1640ThermoFisher Scientific31800-105
SaponinSigma-Aldrich47036
Sodium BicarbonateSigma-AldrichS5761
SpeI-HFNEBR3133S
SuperScript III First-Strand Synthesis kitThermoFisher Scientific18080-051
T4 DNA LigaseThermoFisher Scientific15224017
Thiophosphate ester antibodyAbcamAb92570

References

  1. World Health Organization. . World Malaria Report 2023. , (2023).
  2. Rosenthal, P. J., Asua, V., Conrad, M. D. Emergence, transmission dynamics and mechanisms of artemisinin partial resistance in malaria parasites in Africa.

Explore More Articles

Chemistry

This article has been published

Video Coming Soon

JoVE Logo

個人情報保護方針

利用規約

一般データ保護規則

研究

教育

JoVEについて

Copyright © 2023 MyJoVE Corporation. All rights reserved